A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients

Randomised, double-blind, placebo-controlled Phase II study in ICU patients with depressive symptoms comparing IV ketamine 0.5 mg/kg once daily for three consecutive days versus saline placebo.

Primary aim is to evaluate efficacy and safety of repeated low-dose ketamine infusions for depressive symptoms in critically ill patients; assessments include PHQ-9 changes and safety/vital-sign monitoring.